The antiretrovirals tenofovir, indinavir, atazanavir and lopinavir increase the risk of chronic kidney disease (CKD)
- PDF / 136,332 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 89 Downloads / 146 Views
1
■ The antiretrovirals tenofovir, indinavir, atazanavir and lopinavir increase the risk of chronic kidney disease (CKD) in patients with HIV, according to data from the EuroSIDA study. The incidence of CKD increased from 0.7/100 person-years (95% CI 0.5, 0.8) at baseline to 2.4/100 person-years (1.7, 3.0) following ≥ 4 years of exposure to tenofovir. Similarly, the incidence of CKD increased from 0.6 (0.5, 0.7) to 1.9 (1.4, 2.3) with exposure to indinavir, 0.8 (0.7, 1.0) to 3.9 (2.2, 5.5) with atazanavir, and from 0.9 (0.7, 1.1) to 1.8 (1.3, 2.3) with lopinavir. Increasing cumulative exposure to these drugs was independently associated with significantly increased rates of CKD. No other antiretrovirals appeared to be associated with CKD. Kirk O, et al. Chronic Kidney Disease and Exposure to ART in a Large Cohort with Long-term Follow-up: The EuroSIDA Study. 17th Conference on Retroviruses and Opportunistic Infections : abstr. 107LB, 16 Feb 2010. 803008749 Available from: URL: http://retroconference.org/2010
0114-9954/10/1294-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 27 Mar 2010 No. 1294
Data Loading...
